New approaches for toxicity characterization and risk assessment have focused on in vitro high-throughput screening assays and biological pathways of chemical effects as a way to overcome the ethical, efficiency and cost concerns of traditional testing approaches, while providing adequate hazard information to support risk assessments in the future (Bhattacharya et al., 2011; Cote et al., 2012; Judson et al., 2011; NRC, 2007) . Different mechanistic frameworks have been developed in order to facilitate a biological pathway based approach to chemical assessment including mode of action (MOA), toxicity pathways, pathways of toxicity, and adverse outcome pathways (AOPs) Boobis et al., 2006 Boobis et al., , 2008 Kleensang et al., 2013; NRC, 2007; Sonich-Mullen et al., 2001; see Willet et al., 2014, for review) . Both MOA analysis and the AOP concept are pragmatic frameworks that provide structured, transparent, and hypothesis-based approaches for relating in vitro assay data and biological pathways to adverse outcomes (AOs) of regulatory concern Meek et al., 2014) .
The AOP concept is being broadly investigated as a tractable approach to understand and characterize the critical biological events leading human and ecological health impacts and is currently in use by the Organization for Economic Cooperation and Development (OECD) to harmonize international efforts in chemical assessment (Garcia-Reyero, 2015 ; http://www.oecd. org/chemicalsafety/testing/adverse-outcome-pathways-molecularscreening-and-toxicogenomics.htm). Unlike mode of action analysis, an AOP is chemical agnostic and does not consider toxicokinetics as part of its framework (Meek et al., 2014; OECD, 2103a ). An AOP is a pathway leading to an effect of regulatory concern where a chemical or other stressor causes a molecular initiating event (MIE, eg, receptor binding), leading to key events (KEs, eg, cellular change), and an AO (eg, cancer or decrease in growth) all causally linked together. Extensive guidelines and strategies have recently been described by OECD (2013a,b) and Villeneuve et al. (2014a,b) for the general development of AOPs, use of AOPs for chemical screening and prioritization in fish development (Villeneuve et al., 2014c; Volz et al., 2011) , use of AOPs in ecological hazard and risk assessment (Groh et al., 2015a, b; Kramer et al., 2010) , and use of AOPs in Integrated Approaches to Testing and Assessment (IATA; Rovida et al., 2015; Tollefsen et al., 2014) . Major regulatory programs have also begun to incorporate AOPs for chemical screening (eg, Kleinstreuer et al., 2014; USEPA, 2011) .
Although approaches for assessing the scientific support underlying AOPs and their application Meek et al., 2014; Patlewicz et al., 2015 and references therein) have been proposed, little has been discussed about how much confidence is needed, or how complete a pathway or an AOP should be, before use in a specific application. Here we review the scientific confidence of AOPs that support regulatory efforts and use 4 examples to explore how complete and confident one should be in an AOP before use for a specific purpose in a regulatory application. This is an important question since development of complete AOPs with 'high' scientific support or confidence requires significant effort on the part of researchers and developers. Development and use of AOPs is an iterative process where even partial AOPs or AOPs with 'low' confidence can be useful for specific regulatory purposes. The development and application of AOPs is likely to increase with the knowledge that even partial AOPs are useful for specific purposes.
Critical to the use of AOPs is a measure of confidence that the overall pathway is realistic, contains all essential causal events and that sufficient evidence exists to support each event and relationship leading to an outcome of regulatory interest. The level of evidence and confidence in the data used in decisions varies depending on the problem formulation and the context of decisions being made ( Fig. 1 ; Meek et al., 2014; Patlewicz et al., 2015) . Therefore, AOPs can be useful at many stages of 'completeness'-from the prioritization level, where less evidence and less confidence may be required, to risk assessment decisions that impact use of chemicals, where large amounts of evidence and the highest levels of scientific confidence are required. Ultimately, if an AOP can demonstrably increase confidence in a decision it will likely be useful in regulatory decision making regardless of its completeness.
CONFIDENCE IN AOPs
Two general approaches have been proposed for assessing confidence in AOPs, each of which provides valuable schema for documenting the data supporting confidence in an AOP. The first focuses on the logic and scientific evidence underpinning an AOP. An adaption of Bradford-Hill criteria for assessing causality, first used in assessing the value of MOA pathways (Boobis et al., 2008; Meek et al., 2014) , has been developed to transparently evaluate the plausibility and scientific support for elements of an AOP Hill, 1965; OECD, 2013b) . Here, confidence is based on expert judgment of the amount and quality of data supporting (1) Biological plausibility of KE relationships; (2) Essentiality of KEs in context of the entire AOP; and (3) Empirical support for dose-response, temporality, and consistency of KE relationships. A second, complementary approach, proposed by Patlewicz et al. (2015) focuses on the scientific confidence in the assays used, development of predictive models and applicability and acceptance in the regulatory community. This framework is composed of (1) Development of an AOP using OECD guidelines (OECD, 2013b), (2) Mapping of assays to KE in an AOP, (3) Analytical validation of assays, (4) Predictive model development, (5) Qualification of predictive models, 6. Utilization for specific purposes (define where sufficient scientific confidence exists to support use in a specific purpose eg, prioritization, formation of chemical categories, IATA, prediction of in vivo responses, etc.), and (7) Regulatory acceptance. In each framework, determining and documenting KE relationships are an essential element of an AOP. Using the AOP evaluation approach of the OECD as applied by Becker et al. (2015) a qualitative, overall evaluation of low, moderate, or high confidence in an AOP can be derived. The approach recommended by Patlewicz et al., (2015) provides guidance on assessing not only confidence in the components and the over all AOP, but confidence in an AOP with respect to regulatory applications.
Evaluating the plausibility and supporting evidence for KEs and linkages helps identify gaps and uncertainties in AOPs which, in turn, defines the confidence with which the AOPs can be used to support prediction of the AO from different KEs or the MIE. Although complex AOP networks are needed in most cases to fully describe real-world hazard scenarios (GarciaReyero 2015; Villeneuve et al., 2014b) , biological pathways/processes represented in individual AOPs may be sufficient to increase understanding of low confidence data. Although a comprehensive set of assays is unlikely to be available for all KEs, even in a single AOP, a subset, or battery, of assays measuring select KEs can be useful in making a hazard identification since causal linkages between KEs enable inference of the status of an intervening event, if the two neighboring KEs are both measured (see Patlewicz et al., 2015) .
LEVELS OF CONFIDENCE IN AOPS AND USE IN DIFFERENT REGULATORY APPLICATIONS
AOPs with different degrees of completeness (identification of all essential events, broad scientific evidence supporting all relationships between events, and a causal pathway linking the MIE to the AO) can be useful in decreasing the uncertainty of decisions (Fig. 1) . To illustrate the suitability of AOPs for different regulatory applications, we examined 4 different case studies having different levels of completeness and confidence in order to examine how much information is needed in an AOP for different regulatory applications. We used the AOP for Membrane disruption (Narcosis) leading to respiratory failure (Fig. 2a) and the AOP for Hepatocellular proliferation leading to cancer as examples of how 'incomplete' or lower confidence AOPs are valuable. We also used the AOP for Covalent binding to proteins leading to skin sensitization and the AOP for Aromatase inhibition leading to reproductive dysfunction in fish as examples of complete or nearly complete AOPs that have been documented as having high confidence Patlewicz et al., 2015, respectively) .
'Low' Confidence AOPs Low confidence AOPs generally do not have sufficient information on every essential event and/or KE relationship leading to an Adverse Outcome. However, AOPs with MIE or KEs that are linked to the AO through well-defined mechanistic information, statistical, or quantitative models can still be useful in predicting chemical effects. For example, the pathway for Membrane disruption (Narcosis) leading to respiratory failure (Fig. 2a) is an AOP with poor scientific confidence and partial completeness because of its general MIE and uncertainty about the exact nature of the KEs leading to the AO. Nearly 60% of industrial organic chemicals can be characterized as nonpolar narcotics (Opperhuizen and Van Wezel, 1995 ). An important characteristic of narcotic chemicals is that the effects are reversible. Nonpolar and polar narcotics diffuse into membranes based on their lipophilicity, described by their octanol-water partition coefficients (logK ow ), rather than binding to a specific receptor (MacKay et al., 2009) . As a result of its general MIE, a complete AOP with causal relationships of high scientific confidence has been difficult to delineate. At least two different pathways have been described. The first outlines a generalized pathway leading to a loss of equilibrium and mortality at the organismal level through changes in cellular respiration and metabolic rate as a result of effects in membrane bound processes . The second is focused on disruption of epithelium of primary and secondary lamellae in gills resulting in pathologic alterations (hypertrophy and oedema) ultimately causing hypoxia and respiratory failure (Volz et al., 2011) . Although the chemical properties triggering narcosis (accumulation in biological membranes) are well established, specific linkages to all steps leading to the AOs are neither fully defined nor characterized in either example. The strong correlation of acute aquatic toxicity to logK ow of nonpolar narcotics has been used to develop highly predictive QSAR models, which is not always possible for polar narcotics (Dom et al., 2012b) . Although useful for predicting speciesspecific acute toxicity, these QSARs do not address a fundamental understanding of the KEs and links between them and the chronic AOs affecting populations that are relevant for risk assessment. Assays at other levels of functional organization (ie, intermediate KEs) have been developed that may be of use in better defining KEs for the narcosis AOP. For example, bacterial gene profiling assays including reporter genes for membrane damage (Dom et al., 2012a) , neutral red assay for membrane leakage (Fautz et al., 1991) , time-resolved spectroscopy on energy-transducing membranes to distinguish baseline toxicants and uncouplers (Escher and Schwarzenbach, 2002) , and a submitochondrial particle assay (Argese et al., 2001) are currently available. Importantly though, causal linkages between KE have yet to be established. The current narcosis pathway fails to explain certain species sensitivity differences in fish acute and chronic toxicity and differences in response to chemical enantiomers (Sandermann et al., 2008) . As a result, assessment factors derived for narcotic chemicals to provide ecosystem protection from a chemical fail to provide ecological realism for risk assessment resulting in uncertainties in understanding real environmental risk outcomes for both single and multichemical exposure.
Utilization of 'low' confidence AOPs for specific purposes. In a risk assessment context, confidence in applying the current narcosis AOP to understanding homology of pathways across species is limited due to missing causal linkages between KEs, particularly those linking KE to chronic phenotypic responses. However, a recent evidence-based hypothesis involving sarco/endoplasmic reticulum Ca 2þ
ATPase pump inhibition resulting in perturbed mitochondrial functionality provides a significant step forward in understanding the mechanisms involved in narcosis (Antczak et al., 2015) . In addition it provides a tangible possibility for better understanding of mechanistic, and potentially quantifiable, links to chronic endpoints and population effects.
Even though the narcosis AOP can be rated as having low confidence, based on OECD guidance, the lipophilicity of nonpolar chemicals is sufficiently correlated with acute and chronic toxicity to be useful for development of QSARs in categorization applications (Austin and Eadsforth, 2014; Claeys et al., 2013; Veith et al., 1983; Verhaar et al., 1992) . The currently accepted narcosis QSAR and AOP are being used for prioritization and read-across purposes without the need for full understanding of all KEs or defining all causal links between MIE, KEs, and the AO (OECD, 2009a; Russom et al., 1997; Verhaar et al., 1992) . The narcosis QSAR is the basis of nonspecific toxicity models included in the EpiSuite software used by the USEPA for actions under the Toxic Substances Control Act (USEPA, 2009; http:// epa.gov/ oppt/newchems/tools/21ecosar.htm). The EpiSuite narcosis model has also been included in the OECD QSAR Application Toolbox (OECD, 2009b) to address the European Union legislation Registration, Evaluation, Authorization, and Restriction of Chemicals (European Parliament, 2006 AOP for Hepatocellular proliferation leading to cancer, an AOP of moderate confidence, where the MIE is unknown, but mechanistic and statistical data links activation of a KE to cancer (Fig. 2b) . The AOP is based on a MOA established to explain 1,4-dioxane chemically induced liver cancer (USEPA, 2013). Currently, toxicological data provides sufficient evidence to establish KEs and their relationships to the AO of cancer. The MOA is believed to involve either the KE cell proliferation in the absence of liver cytotoxicity leading to hyperplasia and tumor formation (USEPA, 2013) or the KE of liver cytotoxicity followed by regenerative hyperplasia and tumor formation (Dourson et al., 2014) . The MOA hypothesis for liver tumors involving sustained proliferation of spontaneously transformed liver cells is supported by evidence that 1,4-dioxane is a tumor promoter in mouse skin and rat liver bioassays (King et al., 1973; Lundberg et al., 1987) . Dose-response and temporal evidence also support the occurrence of cell proliferation prior to the development of liver tumors but suggest that cytotoxicity is not a required precursor event (JBRC, 1998; Kociba et al., 1974) . Liver tumors have also been observed in female rats and female mice in the absence of lesions indicative of cytotoxicity (JBRC, 1998; Kano et al., 2009; NCI, 1978) . The confidence in the early events of AOP is moderate due to a lack of data regarding a plausible dose response and temporal progression from cytotoxicity to cell proliferation and eventual liver tumor formation (USEPA, 2013) . This combined with the high confidence in the KE tumorigenesis leading to the AO of cancer ranks this AOP as a moderate, though incomplete, AOP.
The uncertainty associated with KEs within an AOP is a particular concern for regulatory purposes. Although there are a number of ways that uncertainty can be addressed with further validation and/or experimental determination, existing datasets can be mined using computational biology to increase knowledge and therefore the certainty, of an AOP while reducing animal use. We identified a publically available gene expression dataset for 1,4-dioxane to illustrate how additional information can be added to either support or add novel information for any given AOP. The gene expression data set represents a 3, 14, and 28-day time-course of gavage exposure to 1,000 mg/kg/day 1,4-dioxane as part of a larger carcinogen study in rats . The data set was evaluated using a dynamical modeling approach to identify molecular functions that may be perturbed earlier in exposure prior to observation of apical effects. To aid in interpretability we first clustered similar gene expression profiles together using a self-organizing tree algorithm (Tö rö nen et al., 1999) . Additional data-points were then interpolated between the available time points allowing for a smoother average of clustered genes and permitting a better comparison between clusters. Clusters with <10 genes were removed to further simplify the resulting model. The resulting dataset was then used as an input to a dynamical modeling approach based on mutual information, TDARACNE (Zoppoli et al., 2010) .
The resulting network was a hierarchical organization of clusters affected by 1,4-dioxane with direction of dependence between the identified clusters (Fig. 3) . The network provides information permitting development of hypotheses as to what KEs may be sufficient to cause a given AO, in this case induction of tumors by exposure to 1,4-dioxane. Each cluster of genes was functionally annotated with the information present in the manually curated Ingenuity Pathway Analysis database for gene, protein, and disease interactions (Ingenuity.com). Many of the functions and temporal progression of gene clusters were consistent with functions observed in both toxicological data and the AOP (Fig. 2b) . Cluster 1, one of the earliest clusters in the directed network, was enriched for Bone Morphogenic Protein (BMP) and Fibroblast Growth Factor (FGF) signaling consistent with the KEs Regenerative cell proliferation and Cell proliferation in the absence of cytotoxicity that occur at the beginning of the AOP. Cluster 9, at the end of the directed network, is enriched for functions in the coagulation system, Atheriosclerosis signaling, and Role of tissue factor in cancer. These functions are known to be involved, or dysregulated, in hyperplasia or tumors, the last KE in the AOP before impact on survival. Tissue factor, a transmembrane glycoprotein, is involved in activating the coagulation cascade and is expressed by tumor cells promoting growth and metastasis (Kasthuri et al., 2009) . Tatsumi et al. (2009) found decreases in prothrombin and coagulation factors during direct hyperplasia in mice induced by 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene and coagulation disorders associated with cancer are well documented (Falanga et al., 2103; Kvolik et al., 2010) .
The greatest uncertainty in the AOP Hepatocellular proliferation leading to cancer surrounds the MIE and data supporting a KE for either cytotoxicity leading to cell proliferation or for cell proliferation in the absence of cytotoxicity. Computational analysis suggests that changes in BMP and FGF signaling, hepatic fibrosis, and inflammation (IGF-1 and CD-40 signaling) are followed by NF-kB signaling in the progression towards tumor formation and dysregulation of coagulation cascades. Literature evidence supports these relationships. Disruption of the balance between WNT-FGF-Notch and BMP-Hedgehog signaling pathways in stem and progenitor cells has been related to cancer initiation (Katoh et al., 2007) . Point mutations, chromosomal aberrations, epigenetic effects and inflammation can disrupt this balance resulting in hepatocellular carcinoma (Moeini et al., 2012) . NF-kB plays a significant role in controling inflammation and chronic inflammation has been shown to lead to liver cancers via the 'inflammation-fibrosis-cancer axis' (Elsharkawy and Mann, 2007) . These observations suggest that 1,4-dioxane could lead to tumor initiation and cellular proliferation.
Although no data are available on its epigenetic effects, 1,4-dioxane has been demonstrated to cause a dose responsive increase in hepatocellular necrosis and inflammation related nonneoplastic lesions in livers of male B6C3F1 mice (Dourson et al., 2014; NCI, 1978) . Single cell necrosis and inflammation were also observed in livers of male F344/DuCrj rats exposed to 1,4-dioxane via inhalation or drinking water for 13 weeks Kasai et al., 2009) . 1,4-dioxane is metabolized in rat liver by cytochrome P4502E1 suggesting that prolonged exposure could generate free radical species (Nannelli et al., 2005) . Alternatively, hepatocellular necrosis could also result in release of reactive oxygen species. Reactive oxygen species have been shown to increase FGF-2 signaling in pulmonary arterial smooth muscle cells systems (Black et al., 2008) . This leads to the hypothesis that 1,4-dioxane acts through an AOP where FGF signaling and NF-kB signaling is deregulated, either directly by causing necrosis, or indirectly through reactive oxygen species, which then increase inflammatory responses, thereby leading to cell proliferation and ultimately tumor formation.
Utilization of 'moderate' confidence AOPs for specific purposes. Use of an AOP for chemical read across applications or informing an integrated testing and assessment strategy requires an understanding of the relationships between the KE under consideration with respect to other KEs in the pathways as well as to the AO. Partial AOPs can be useful in a regulatory context, especially where significant information exists linking KEs to an AO (USEPA, 2013; Ankley and Jensen, 2014) . The partial AOP is currently suitable to function as a framework for communicating the potential of a chemical to cause cancer via hepatocellular proliferation. It is also suitable to predict cancer by activation of the KE tumor formation. However, while the KE of tumor formation in animals is considered sufficient information to infer cancer risk in humans, the AOP also suggests potential areas for development of assays for KEs linked to tumor formation that can reduce or eliminate animal use such as dysregulation of BMP and FGF signaling or disruption of the balance between WNT-FGF-Notch and BMP-Hedgehog signaling pathways in stem and progenitor cells. Overall, this partial AOP with a moderate confidence has sufficient scientific data to support categorization of 1,4-dioxane as a likely carcinogenic to humans given appropriate exposure and dose conditions (USEPA, 2013) . This AOP case study demonstrates that partial AOPs can be used for specific regulatory purposes as long as in vivo or in vitro assay dose response data can be linked to a regulated outcome.
'High' Confidence AOPs AOPs with high levels of confidence are pathways where MIEs/ KEs have been causally linked and where quantitative relationships between all KEs and the AO of regulatory concern have been established. Here we examine the completeness and use of two high confidence AOPs, the AOP for Skin sensitization initiated by covalent binding to proteins (Fig. 2c) , and the AOP for Aromatase leading to reproductive dysfunction in fish (Fig. 2d) .
The scientific data supporting the AOP for Skin sensitization initiated by covalent binding to proteins has been extensively reviewed elsewhere (MacKay et al., 2013; OECD, 2012; Patlewicz et al., 2015; van der Veen et al., 2014) . Skin sensitization occurs when a substance induces an allergic response following skin contact, which can then lead to allergic contact dermatitis (OECD, 2012) . The pathway is initiated with binding of a sensitizing agent to skin protein, activation and production of cytoprotective pathways and inflammatory cytokines in Keratinocytes with concomitant increase in inflammatory cytokines in Dendritic cells, followed by activation and proliferation of T-cells in Lymph nodes which ultimately will result in allergic contact dermatitis on challenge ( Fig. 2c ; MacKay et al., 2013) . There is strong evidence for the qualitative sequence of events depicted in Figure 2c (OECD, 2012) . The series of events from MIE to AO for Skin sensitization initiated by covalent binding to proteins is well established with extensive dose response data and has been ranked as a high confidence AOP (OECD, 2012; Patlewicz et al., 2015) . Empirical evidence from various events in the AOP has value in predicting the potential of a chemical to be a skin sensitizer. However, individually, the assays are inconsistent in predicting the relative potency of a chemical. This has led to efforts to design integrated testing strategies based on the AOP that are more quantitative, or predictive of potency, for application in risk assessment. The development of a more quantitative AOP requires benchmark in vivo data for the apical outcome of allergic contact dermatitis. Many efforts have used the Local Lymph Node Assay (LLNA) as a surrogate as it measures T lymphocyte proliferation at lymph nodes draining the site of chemical application which is a required event that is quantitatively related to skin sensitization (Kimber and Weisenberger, 1989) . However, this assay is not without limitations (eg, it measures a function of induction rather than elicitation of allergy). In addition, measured potency from this assay requires the risk assessor to extrapolate hazard potency from an animal assay to risk in humans (in the context of the relevant chemical exposure) that involves the application of assessment factors to account for uncertainty.
The AOP for aromatase leading to reproductive dysfunction in fish (Fig. 2d) has extensive support for most KE and KE relationships and a detailed analysis of the scientific confidence supporting the AOP has been completed . As a result of the pivotal role of aromatase in the conversion of testosterone to estradiol in vertebrates (Simpson et al., 1994) , aromatase inhibition can lead to a decrease in circulating estradiol, a decrease in liver estrogen receptor activation and vitellogenin egg protein production, impaired ovulation and spawning, and ultimately a decrease in population sustainability in fish ( Fig.  2d ; Ankley et al., 2010) . Overall this AOP has been ranked as high confidence due to the extensive, quantitative information linking KEs in multiple fish species Utilization of 'high' confidence AOPs for specific purposes. High confidence AOPs are suitable for development of quantitative, predictive models that permit extrapolation from in vitro assay measurements to the likeliness of an AO occurring. Currently accepted methods for assessing hazard and risks for skin sensitization in humans revolve around apical endpoint information from animal or human studies at the individual or organ level, such as the LLNA (Gerberick et al., 2007) . In the quantitative risk assessment process, this information is integrated with estimated exposure to humans and Sensitization Assessment Factors are used to account for the uncertainty in extrapolating from simple vehicle matrices to complex formulations, differences in use considerations (eg, site of contact, duration of exposure, etc.) and interindividual variation in sensitivity across populations (Api et al., 2008) . Many current and proposed uses of the AOP revolve around quantitative methods to predict the existing animal data such as the LLNA EC 3 (the effective concentration of a test chemical required to produce a 3-fold increase in the stimulation index relative to vehicle-treated controls). LLNA-based AOPs have utility in risk assessment, classification and labeling, data gap filling, IATA, and hazard identification and characterization where mechanism-based QSARs exist (Roberts et al., 2011; Tollefsen et al., 2014) . Several groups have integrated results from assays of skin sensitization KE to predict LLNA results in a qualitative, semi-quantitative, or quantitative manner (eg, Jaworska et al., 2013; Nukada et al., 2013) . In addition, the AOP has been implemented in the OECD QSAR toolbox to allow assessment of chemicals based on data not only from the MIE or AO, but also using data representing different combinations of KEs (OECD, 2012) .
These approaches are applicable to the process of screening new chemicals and in prioritizing existing chemicals with no data. The confidence in assessments made using these approaches will be limited by the benchmark data on which they are based. A more acceptable approach may be to use the AOP to assess the risk of allergic reaction in humans occurring rather than the existing animal model. This will require the use of human benchmark data and mathematical modeling (Maxwell et al., 2014) . It will also require greater dialogue with regulatory authorities to build an understanding of how weight-of-evidence IATA frameworks are being applied for different risk assessment decisions.
The high confidence aromatase inhibition AOP is useful in a number of applications. Well-validated assays are available for the MIE and many of the KEs up to the individual level. Assays for the MIE and many of the KEs have been implemented into screening and assessment programs (Hecker et al., 2011) . Although no defined programs are in place in Europe, the USEPA has implemented aromatase inhibition assays into the high-throughput screening program ToxCast (Rotroff et al., 2013) in addition to the Endocrine Disruptor Screening Program where the assays for most events from the MIE to the AO are used in prioritization (tier 1) and assessment assays (tier 2; USEPA, 1998 USEPA, , 2011 USEPA, and 2012 . The egg protein Vitellogenin (VTG) has also long been used in monitoring programs to assess potential effects of chemicals in field populations (eg, Schmitt and Dethloff, 2000) . A quantitative AOP for this pathway is emerging based on mechanistic models that predict changes in estradiol production from ovaries of fathead minnow in the presence of the aromatase inhibitor fadrozole joined to models that utilize VT Glevels to predict population level effects (Breen et al., 2013; Shoemaker et al., 2010) . Based on the confidence in the pathway, the high reproducibility of assays measuring different events, the scientific evidence linking KEs to the outcome, both mechanistically and quantitatively, and the number of different species of fish that the pathway has been demonstrated in, including fathead minnow, zebrafish, medaka, and stickleback, this AOP is suitable for use in regulatory and risk assessment applications.
Comparison of AOPs With Different Confidence and Completeness
The 4 case studies presented earlier represent AOPs with different levels of completeness and overall scientific confidence. Despite the range of completeness (incomplete to complete) and confidence (low to high), each AOP was suitable for specific regulatory purposes. Both the narcosis and hepatocellular proliferation AOPs are incomplete in identification of essential causal events (Fig. 2) . The narcosis pathway has conflicting hypothesis about the necessary KE leading from membrane accumulation to narcosis. The hepatocellular proliferation pathway has no MIE that has been identified. Despite their incompleteness, both AOPs are useful in specific applications because of the statistical relationship of the outcome of concern to the MIE in the case of narcosis and a KE in the case of hepatocellular proliferation. Similarly, statistical linkages between the KE of decrease in plasma VTG production and the KE decrease in egg production in fathead minnow have been used for estimating potential population level impacts based on the high confidence in relationships in the aromatase inhibition AOP Miller et al., 2007) . The high confidence skin sensitization AOP is well defined with essential events and assays. Response relationships between KE in the skin sensitization AOP also play a critical role in development of models to interpret a battery of assays representing the skin sensitization KE (Jaworska et al., 2013; Pirone et al., 2014; reviewed in van der Veen et al., 2014) . Additionally, the high confidence in the MIE, early KE and the relationships between them, allow assays from the aromatase inhibition AOP and skin sensitization AOP to be used in prioritization efforts. Based on these comparisons, it is clear that having a significant statistical or quantitative relationship (a high confidence relationship) between events and/or the AO relationships is a common characteristic of AOPs, both incomplete and complete, that have some specific regulatory use.
Acceptance of AOPs for Regulatory Applications
Regulatory agencies have long used mechanistic or MOA frameworks for hazard characterization and risk assessments (Boobis et al., 2006; reviewed in Julien et al., 2009; USEPA, 2005) . Unlike the MOA framework, the AOP framework is not chemical specific therefore pathways developed should be more applicable to specific purposes such as categorization or grouping and be more adaptable to different chemicals (Garcia-Reyero, 2015) . The AOP framework is very similar to MOA analysis and incorporates mechanistic information, therefore the utility of AOPs lies in their being at least as useful as the tools that regulators currently possess, or the techniques currently employed by regulators.
The utility of an AOP for a particular application will be dependent upon whether or not it reduces uncertainty for decisions being made. In the case of cancer caused by 1,4-dioxane AOP, a MIE and early KEs were unknown, yet it is useful for risk assessment because the linkage of chemical exposure to occurrence of cancer exists and the existing KEs support the development of the AO. Strong predictive relationships between the MIE or KE and the AO allow a poorly described AOP, such as Narcosis, to be used in screening or categorization applications considering in particular acute toxicity, without needing to develop fully robust links between KEs and the AO. Stronger scientific confidence in KE relationships are required to enable AOPs to be used to understand fully pathway homology across species. They permit development of quantitative models for extrapolating difficult to measure outcomes such as population level effects from KEs as seen in the Aromatase inhibition leading to reproductive dysfunction in fish. Confidence in linkages between different events can be increased through analysis of large data sets such as transcriptomics data sets, as in the case of cancer caused by 1,4-dioxane, where biological pathways underlying organ or cellular level effects are connected via time series analysis.
Improving AOPs for Regulatory Applications
AOPs offer a valuable framework not only for aggregating information in a biologically plausible manner for communication, but also as a tool for risk assessment. In order to maximize the AOP concept for application to regulatory situations, several improvements can be made. Current approaches for documenting and establishing scientific confidence in the events and pathways are credible and transparent but need to incorporate semi-quantitative or quantitative measures of confidence such as weight of evidence, multicriteria decision making, or Bayesian modeling in order to facilitate the use of AOPs in riskbased decisions . Toxicologists should investigate the relationship of more than one KE in an experiment, preferably anchored to the AO, so that more data is available to describe the dose-response relationships between events. Although biologically plausible pathways are necessary for an AOP, an incomplete AOP with high confidence relationships between events can be useful in specific applications requiring prediction of chemical effects using high-throughput assays or for predicting an outcome based on an early KE that is easily assayable. Future efforts to incorporate AOPs into risk assessment will need to account for multiple interacting pathways or networks of AOPs (Garcia-Reyero, 2015; Villeneuve et al., 2014b 
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